News

Following the popularity of the first expert meeting on prevention held in January 2015, a second European HIV Prevention Summit was held on 29-31 January 2016. Organised jointly by the European AIDS Treatment Group (EATG) and AVAC, the meeting brought pharmaceutical companies, public health experts, academics and leading scientists in the field of prevention research together with over 50 European community based advocates for three days of information exchange and debate in Brussels.  

Please read and share widely the closing report from the meeting. The report contains live links to the presentations given at the meeting.

The European Community Advisory Board (ECAB), the scientific working group of the EATG has been pointing out the low representation and recognition of clinical research centres in Eastern Europe and Central Asia for several years. EATG/ECAB often encountered the explanation that such centres were not known or insufficiently represented in the international science and research communities for them to be included in the clinical research process.

Therefore EATG/ECAB, with valuable support from our sponsors, launched a research project to explore the possibilities to conduct clinical trials and studies in communities that are less common on the map for now but can offer good alternatives and possibilities for clinical research. Sergey Golovin, our colleague from Russia, compiled this excellent report.

The UNAIDS Caribbean Sub-regional Office is pleased to provide documents and presentations associated with the Caribbean HLM2016 Consultation conducted via WebEx on Wednesday 9th March, 2016.  

The purpose of this consultation was to engage partners in the Caribbean HIV response in a dialogue on the Continuum of Care, Financing, Human Rights and Key Populations. Your inputs will continue to help shape the Caribbean Sub-regional Road Map for the 2016 High Level Meeting on HIV/AIDS to be held in New York from 8-10 June, 2016. 

The UNAIDS Caribbean Sub-regional Office invites you to participate in a WebEx Meeting to be held from 2-4 pm (Jamaica time) 9 March, 2016 for the English-speaking Caribbean and Haiti. This online dialogue will be hosted by UNAIDS Latin American and Caribbean Offices as continuation of the on-going stakeholder consultations that are being held at global, regional and country levels to develop the Caribbean Sub-regional Road Map for the 2016 High Level Meeting on HIV/AIDS to be held in New York City, NY, U.S.A from 8-10 June, 2016. 

Today we spotlight Executive Committee member Gavin A Cloherty, PhD. Dr. Cloherty’s recent publication, “The Role of Serologic and Molecular Diagnostic Assays in the Identification and Management of Hepatitis C Virus Infection,”(1) was in the December 2015 issue of Journal of Clinical Microbiology. Dr. Cloherty talks about his work in a brief written interview with the Forum. 

The Mayo Clinic Children's Research Center (CRC) seeks an accomplished Childhood Disease Clinician-Investigator who will expand our Pediatric Research Enterprise and help grow the pediatric practice in one of the CRC areas of focus: cancer, transplantation, immunology, infection, cardiac, and neurological disorders.

This institutionally-funded clinician-investigator position is intended to develop a new independent translational research program leading to important discoveries and clinical applications thereof that will impact currently unmet needs of pediatric patients.

UNAIDS will be hosting a series of virtual dialogues on issues that will likely be central in the 2016 High-Level Meeting (HLM) Political Declaration. 

The dialogues will start with a brief update on the HLM process and background on the particular topic area, including how it has been addressed in past Declarations and any developments that may affect debate on the topic at this year's HLM. 

Most of the hour will be reserved for open dialogue.  The discussions will inform UNAIDS' work on the HLM, identify ways UNAIDS can partner with and support civil society, and explore how we can work together on common goals. 

The ISHIELD Scientific Program Committee welcomes virologists, scientists, immunologists, lab professionals, clinicians and educators/course directors in the field of HIV, hepatitis or emerging infectious diseases with the opportunity to present and publish innovative scientific investigations or state-of-art studies to an audience of HIV and professionals from around the world!

Please kindly read the submission guidelines before submitting your abstract.

The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.

The Forum for Collaborative HIV Research would like to spotlight Executive Committee member Jean-Michel Pawlotsky.  Dr. Pawlotsky recent publication Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C”(1) in the December 2015 issue of Journal of Hepatology.  In a brief written interview the Forum asked Dr. Pawlotsky about this work.